Anti-Human CCR4 Therapeutic Antibody (Mogamulizumab)

Cat. No.: TAB-187
This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Product Overview</th>
<th>Recombinant monoclonal antibody to CCR4. Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Host Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Specificity</td>
<td>Tested positive against native human antigen.</td>
</tr>
<tr>
<td>Target</td>
<td>CCR4</td>
</tr>
<tr>
<td>Immunogen</td>
<td>KLH conjugate CCR4 partial peptide</td>
</tr>
<tr>
<td>Derivation</td>
<td>Humanized (from mouse)</td>
</tr>
<tr>
<td>Species Reactivity</td>
<td>Human</td>
</tr>
<tr>
<td>Type</td>
<td>IgG1 - kappa</td>
</tr>
<tr>
<td>Expression Host</td>
<td>CHO</td>
</tr>
<tr>
<td>Trade name</td>
<td>Poteligeo</td>
</tr>
<tr>
<td>CAS</td>
<td>1159266-37-1</td>
</tr>
<tr>
<td>Generic Name</td>
<td>Mogamulizumab</td>
</tr>
<tr>
<td>MW</td>
<td>146.44 kDa</td>
</tr>
<tr>
<td>Purity</td>
<td>&gt;95.0% as determined by analysis by SDS-PAGE.</td>
</tr>
<tr>
<td>Applications</td>
<td>Neut, ELISA, IF, IP, FuncS, FC, ICC</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Application Notes</td>
<td>The CCR4 antibody has been reported in applications of FC, Inhib, Cyt, Agonist, IHC, RT-PCR, Migration. FC: For flow cytometric analysis, cells were stained at 4°C with fluorescein isothiocyanate-conjugated anti-human CCR4. Migration assay: In vitro cell migration was assayed using a CytoSelect 96-Well Cell Migration Assay kit (5 μm, Fluorometric Format) according to the manufacturer's protocol.</td>
</tr>
<tr>
<td>Formulation</td>
<td>C_{6520}H_{10072}N_{1736}O_{2020}S_{42}</td>
</tr>
<tr>
<td>Size</td>
<td>1mg</td>
</tr>
<tr>
<td>Storage</td>
<td>Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.</td>
</tr>
<tr>
<td>Related Disease</td>
<td>Asthma</td>
</tr>
</tbody>
</table>

**BACKGROUND**

**Introduction**

High affinity receptor for the C-C type chemokines CCL17/TARC and CCL22/MDC. The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. Can function as a chemoattractant homing receptor on circulating memory lymphocytes and as a coreceptor for some primary HIV-2 isolates. In the CNS, could mediate hippocampal-neuron survival.

**Alternative Names**

Mogamulizumab;Poteligeo;1159266-37-1;KW-0761;KM8761;AMG-761;Poteligeo;CCR4;chemokine (C-C motif) receptor 4;C-C chemokine receptor type 4;CC CKR 4;CD194;ChemR13;CKR4;CMKBR4;k5 5;CCR-4;C-C CKR-4;chemokine (C-C) receptor 4;K5-5;CC-CKR-4;HGCN:14099;MGC88293;

**Gene ID**

1233

**UniProt ID**

P51679